专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005110056A3 COMPOSITIONS COMPRISING ADDL RECEPTOR SYNGAP 审中-公开
标题翻译：包含ADDL受体SYNGAP的组合物
公开(公告)号：WO2005110056A3
公开(公告)日：2006-07-27
申请号：PCT/US2005017176
申请日：2005-05-16
申请人： UNIV NORTHWESTERN , ACUMEN PHARMACEUTICALS , LACOR PASCALE N , VIOLA KIRSTEN L , LAMBERT MARY P , GONG YUESONG , CHANG LEI , VELASCO PAULINE T , BIGIO EILEEN H , BUNIEL MARIA C , FERNANDEZ SARA J , JERECIC JASNA , CATALANO SUSAN , PRAY TODD , LOWE RAY , KRAFFT GRANT A , KLEIN WILLIAM L
发明人： LACOR PASCALE N , VIOLA KIRSTEN L , LAMBERT MARY P , GONG YUESONG , CHANG LEI , VELASCO PAULINE T , BIGIO EILEEN H , BUNIEL MARIA C , FERNANDEZ SARA J , JERECIC JASNA , CATALANO SUSAN , PRAY TODD , LOWE RAY , KRAFFT GRANT A , KLEIN WILLIAM L
IPC分类号： A61K38/17 , C07K14/47 , C07K14/705
CPC分类号： C07K14/4711 , A61K31/495 , A61K38/00 , G01N33/5058 , G01N2800/2821
摘要： Disclosed and claimed herein are compositions comprising ADDL receptors, related compositions, and related methods. ADDL receptors are typically, but perhaps not exclusively, localized at the post-synaptic density (PSD) of neuronal cells. Related compositions include, but are not limited to, compounds that affect, positively or negatively, ADDL binding to neuronal cells, either via one or more receptors localized at the post-synaptic density (PSD) or otherwise. Related methods include, but are not limited to, procedures to screen for compounds that affect, either positively or negatively, ADDL binding to neuronal cells, either via one or more receptors localized at the post-synaptic density (PSD) or otherwise. Other related methods include, but are not limited to, prevention and treatment of ADDL-related diseases, such as Alzheimer's disease, mild cognitive impairment, Down's syndrome, and the like, using compositions that inhibit, block, or otherwise interfere with ADDL binding to one or more receptors localized at the post-synaptic density of neuronal cells.
摘要翻译：本文公开和要求保护的是包含ADDL受体，相关组合物和相关方法的组合物。 ADDL受体通常但不限于，定位于神经元细胞的突触后密度（PSD）。相关的组合物包括但不限于通过定位在突触后的密度（PSD）或其它方式的一种或多种受体影响ADDL与神经元细胞结合的积极或消极的化合物。相关方法包括但不限于筛选通过位于突触后突变密度（PSD）或其他方式定位的一种或多种受体影响ADDL与神经元细胞结合的化合物的方法。其他相关方法包括但不限于使用抑制，阻断或以其他方式干扰ADDL结合的组合物来预防和治疗ADDL相关疾病，例如阿尔茨海默氏病，轻度认知障碍，唐氏综合征等。位于神经元细胞突触后密度的一个或多个受体。

2. 发明申请

WO2009009768A3 METHODS OF INHIBITING THE FORMATION OF AMYLOID-ß DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUDS 审中-公开
标题翻译：使用乙酰丙酮化合物抑制AMYLOID-β可扩增配体形成的方法
公开(公告)号：WO2009009768A3
公开(公告)日：2009-03-26
申请号：PCT/US2008069878
申请日：2008-07-11
申请人： ACUMEN PHARMACEUTICALS INC , LOOK GARY CHARLES , SCHULTZ LAURI , POLOZOV ALEXANDRE MIKHAYLOVICH , BHAGAT NIKHIL , WANG JIAN , ZEMBOWER DAVID E , GOURE WILLIAM F , PRAY TODD , KRAFFT GRANT A
发明人： LOOK GARY CHARLES , SCHULTZ LAURI , POLOZOV ALEXANDRE MIKHAYLOVICH , BHAGAT NIKHIL , WANG JIAN , ZEMBOWER DAVID E , GOURE WILLIAM F , PRAY TODD , KRAFFT GRANT A
IPC分类号： A61K31/15 , A61P9/10 , A61P25/28
CPC分类号： A61K31/15 , A61K9/1647 , A61K9/1652 , A61K9/1664 , A61K9/204 , A61K31/166 , A61K31/18 , A61K31/34 , A61K31/341 , A61K31/343 , A61K31/357 , A61K31/381 , A61K31/402 , A61K31/404 , A61K31/4045 , A61K31/415 , A61K31/4155 , A61K31/433 , A61K31/44 , A61K31/445 , A61K31/451 , A61K31/495 , A61K31/5375 , C07C251/76 , C07C251/86 , C07C311/08 , C07C311/21 , C07C2601/14 , C07D207/327 , C07D209/34 , C07D209/42 , C07D211/16 , C07D213/82 , C07D231/12 , C07D295/18 , C07D307/52 , C07D307/68 , C07D317/68 , C07D333/38 , C07D333/58 , C07D333/68 , C07D409/12 , C07D417/12 , G01N2333/4709
摘要： Disclosed are methods of inhibiting, regulating, and/or modulating the formation of soluble, globular, non-fibrillar, neurotoxic amyloid ß1-42 oligomers from amyloid ß1-42 monomers using acylhydrazidecompounds. Also disclosed are methods of treating a patient suffering from diseases associated with the formation of soluble, globular, non-fibrillar, neurotoxic amyloid ß1-42 oligomers using acylhydrazidecompounds.
摘要翻译：公开了使用酰肼化合物从淀粉样蛋白β1-42单体抑制，调节和/或调节可溶性，球状，非纤维状，神经毒性淀粉样蛋白β1-42寡聚体形成的方法。还公开了治疗患有与使用酰肼化合物形成可溶性，球状，非纤维状，神经毒性淀粉样蛋白β1-42寡聚物相关的疾病的患者的方法。

3. 发明申请

WO2009009768A8 METHODS OF INHIBITING THE FORMATION OF AMYLOID-ß DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUNDS 审中-公开
标题翻译：使用氰基化合物抑制AMYLOID-β可扩散配体形成的方法
公开(公告)号：WO2009009768A8
公开(公告)日：2010-01-28
申请号：PCT/US2008069878
申请日：2008-07-11
申请人： ACUMEN PHARMACEUTICALS INC , LOOK GARY CHARLES , SCHULTZ LAURI , POLOZOV ALEXANDRE MIKHAYLOVICH , BHAGAT NIKHIL , WANG JIAN , ZEMBOWER DAVID E , GOURE WILLIAM F , PRAY TODD , KRAFFT GRANT A
发明人： LOOK GARY CHARLES , SCHULTZ LAURI , POLOZOV ALEXANDRE MIKHAYLOVICH , BHAGAT NIKHIL , WANG JIAN , ZEMBOWER DAVID E , GOURE WILLIAM F , PRAY TODD , KRAFFT GRANT A
IPC分类号： A61K31/15 , A61P9/10 , A61P25/28
CPC分类号： A61K31/15 , A61K9/1647 , A61K9/1652 , A61K9/1664 , A61K9/204 , A61K31/166 , A61K31/18 , A61K31/34 , A61K31/341 , A61K31/343 , A61K31/357 , A61K31/381 , A61K31/402 , A61K31/404 , A61K31/4045 , A61K31/415 , A61K31/4155 , A61K31/433 , A61K31/44 , A61K31/445 , A61K31/451 , A61K31/495 , A61K31/5375 , C07C251/76 , C07C251/86 , C07C311/08 , C07C311/21 , C07C2601/14 , C07D207/327 , C07D209/34 , C07D209/42 , C07D211/16 , C07D213/82 , C07D231/12 , C07D295/18 , C07D307/52 , C07D307/68 , C07D317/68 , C07D333/38 , C07D333/58 , C07D333/68 , C07D409/12 , C07D417/12 , G01N2333/4709
摘要： Disclosed are methods of inhibiting, regulating, and/or modulating the formation of soluble, globular, non-fibrillar, neurotoxic amyloid ß1-42 oligomers from amyloid ß1-42 monomers using acylhydrazidecompounds. Also disclosed are methods of treating a patient suffering from diseases associated with the formation of soluble, globular, non-fibrillar, neurotoxic amyloid ß1-42 oligomers using acylhydrazidecompounds.
摘要翻译：公开了使用酰肼化合物从淀粉样蛋白β1-42单体抑制，调节和/或调节可溶性，球状，非纤维状，神经毒性淀粉样蛋白β1-42寡聚体形成的方法。还公开了治疗患有与使用酰肼化合物形成可溶性，球状，非纤维状，神经毒性淀粉样蛋白β1-42寡聚物相关的疾病的患者的方法。

4. 发明专利

CA2566619A1 COMPOSITIONS COMPRISING ADDL RECEPTOR SYNGAP 未知
公开(公告)号：CA2566619A1
公开(公告)日：2005-11-24
申请号：CA2566619
申请日：2005-05-16
申请人： ACUMEN PHARMACEUTICALS , UNIV NORTHWESTERN
发明人： BUNIEL MARIA C , FERNANDEZ SARA J , BIGIO EILEEN H , LACOR PASCALE N , JERECIC JASNA , VIOLA KIRSTEN L , KLEIN WILLIAM L , CATALANO SUSAN , PRAY TODD , LAMBERT MARY P , GONG YUESONG , LOWE RAY , CHANG LEI , KRAFFT GRANT A , VELASCO PAULINE T
IPC分类号： A61K38/17 , C07K14/47 , C07K14/705
摘要： Disclosed and claimed herein are compositions comprising ADDL receptors, related compositions, and related methods. ADDL receptors are typically, but perhaps not exclusively, localized at the post-synaptic density (PSD) of neuronal cells. Related compositions include, but are not limited to, compounds that affect, positively or negatively, ADDL binding to neuronal cells, either via one or more receptors localized at the post-synaptic density (PSD) or otherwise. Related methods include, but are not limited to, procedures to screen for compounds that affect, either positively or negatively, ADDL binding to neuronal cells, either via one or more receptors localized at the post-synaptic density (PSD) or otherwise. Other related methods include, but are not limited to, prevention and treatment of ADDL-related diseases, such as Alzheimer's disease, mild cognitive impairment, Down's syndrome, and the like, using compositions that inhibit, block, or otherwise interfere with ADDL binding to one or more receptors localized at the post-synaptic density of neuronal cells.

5. 发明专利

AU2005244013A1 Compositions comprising ADDL receptor syngap 未知
公开(公告)号：AU2005244013A1
公开(公告)日：2005-11-24
申请号：AU2005244013
申请日：2005-05-16
申请人： ACUMEN PHARMACEUTICALS INC , UNIV NORTHWESTERN
发明人： VELASCO PAULINE T , LOWE RAY , CATALANO SUSAN , PRAY TODD , CHANG LEI , KRAFFT GRANT A , KLEIN WILLIAM L , BUNIEL MARIA C , FERNANDEZ SARA J , GONG YUESONG , LAMBERT MARY P , JERECIC JASNA , BIGIO EILEEN H , LACOR PASCALE N , VIOLA KIRSTEN L
IPC分类号： A61K38/17 , C07K14/47 , C07K14/705
摘要： Disclosed and claimed herein are compositions comprising ADDL receptors, related compositions, and related methods. ADDL receptors are typically, but perhaps not exclusively, localized at the post-synaptic density (PSD) of neuronal cells. Related compositions include, but are not limited to, compounds that affect, positively or negatively, ADDL binding to neuronal cells, either via one or more receptors localized at the post-synaptic density (PSD) or otherwise. Related methods include, but are not limited to, procedures to screen for compounds that affect, either positively or negatively, ADDL binding to neuronal cells, either via one or more receptors localized at the post-synaptic density (PSD) or otherwise. Other related methods include, but are not limited to, prevention and treatment of ADDL-related diseases, such as Alzheimer's disease, mild cognitive impairment, Down's syndrome, and the like, using compositions that inhibit, block, or otherwise interfere with ADDL binding to one or more receptors localized at the post-synaptic density of neuronal cells.

6. 发明申请

WO2004019890A3 IN VIVO PRODUCTION OF CYCLIC PEPTIDES FOR INHIBITING PROTEIN-PROTEIN INTERACTION 审中-公开
标题翻译：用于抑制蛋白质 - 蛋白质相互作用的循环肽的生产
公开(公告)号：WO2004019890A3
公开(公告)日：2006-06-15
申请号：PCT/US0327371
申请日：2003-08-30
申请人： RIGEL PHARMACEUTICALS INC , LORENS JAMES B , PRAY TODD , KINSELLA TODD M , BENNETT MARK K
发明人： LORENS JAMES B , PRAY TODD , KINSELLA TODD M , BENNETT MARK K
IPC分类号： G01N33/53 , A61K20060101 , A61K9/00 , C07K1/04 , C12N15/10
CPC分类号： C07K1/047 , C12N15/10 , C12N15/1055 , G01N2500/02
摘要： The present invention relates to methods and compositions utilizing inteins to generate libraries of cyclic peptides in vivo. The present invention also relates to methods for inhibiting protein-protein interaction.
摘要翻译：本发明涉及利用内含肽在体内产生环肽文库的方法和组合物。本发明还涉及抑制蛋白质 - 蛋白质相互作用的方法。

7. 发明专利

CA2692801A1 Methods of inhibiting the formation of amyloid-Beta diffusable ligands using a acylhydrazide compounds. 未知
公开(公告)号：CA2692801A1
公开(公告)日：2009-01-15
申请号：CA2692801
申请日：2008-07-11
申请人： ACUMEN PHARMACEUTICALS INC
发明人： LOOK GARY CHARLES , SCHULTZ LAURI , POLOZOV ALEXANDRE MIKHAYLOVICH , BHAGAT NIKHIL , WANG JIAN , ZEMBOWER DAVID E , GOURE WILLIAM F , PRAY TODD , KRAFFT GRANT A
IPC分类号： A61K31/15 , A61P9/10 , A61P25/28

8. 发明专利

CA2692775A1 Methods of enhancing cognitive function using non-peptidic compounds. 未知
公开(公告)号：CA2692775A1
公开(公告)日：2009-01-15
申请号：CA2692775
申请日：2007-07-12
申请人： ACUMEN PHARMACEUTICALS INC
发明人： KRAFFT GRANT A , PRAY TODD , GOURE WILLIAM F
IPC分类号： A61K31/381 , A61P25/28

9. 发明专利

ES2426501T3 Procedimientos de mejora de la función cognitiva utilizando compuestos no peptídicos 未知
公开(公告)号：ES2426501T3
公开(公告)日：2013-10-23
申请号：ES07812875
申请日：2007-07-12
申请人： ACUMEN PHARMACEUTICALS INC
发明人： KRAFFT GRANT A , PRAY TODD , GOURE WILLIAM F
IPC分类号： A61K31/381 , A61P25/28
摘要： Compuesto seleccionado de entre el grupo que consiste en: [3-oxo-3-(1-metil-1H-pirazol-5-il)-1-trifluorometil-prop-(Z)-iliden]-hidrazida del ácido 2-hidroxi-benzoico; [3-oxo-3-tiofen-2-il-1-bifluorometil-prop-(Z)-iliden]-hidrazida del ácido 2-hidroxi-benzoico; [3-oxo-3-furan-2-il-1-trifluorometil-prop-(Z)-iliden]-hidrazida del ácido 2-hidroxi-benzoico; N-(2-Metoxi-fenil)-2-oxo-2-{N'-[3-oxo-3-tiofen-2-il-1-trifluorometil-prop-(Z)-iliden]-hidrazino}-acetamida; Éster etílico del ácido 2-{[1-(2-hidroxi-3-metoxi-fenil)-met-(E)-iliden-hidrazinooxalil]-amino}-6-metil-4,5,6,7-tetrahidro-benzo[b]tiofen-3-carboxílico, Éster etílico del ácido 2-{[1-(2-hidroxinaftalen-1-il)-met-(E)-iliden-hidrazinooxalil]-amino}-6-metil-4,5,6,7-tetrahidrobenzo[b]tiofen-3-carboxílico; Éster etílico del ácido 2-{[1-(2-hidroxifenil)-met-(E)-iliden-hidrazinooxalil]-amino}-6-metil-4,5,6,7-tetrahidrobenzo[b]tiofeno-3-carboxílico; 2-(3-etil-5-hidroxi-5-(trifluorometil)-4,5-dihidro-1H-pirazol-1-il)-N-(2-metoxifenil)-2-oxoacetamida; 2-(5-hidroxi-3-propil-5-(trifluorometil)-4,5-dihidro-1H-pirazol-1-il)-N-(2-metoxifenil)-2-oxoacetamida; 2-(5-hidroxi-3-isopropil-5-(trifluorometil)-4,5-dihidro-1H-pirazol-1-il)-N-(2-metoxifenil)-2-oxoacetamida; 2-(5-hidroxi-3-isobutil-5-(trifluorometil)-4,5-dihidro-1H-pirazol-1-il)-N-(2-metoxifenil)-2-oxoacetamida; (5-hidroxi-3-propil-5-(trifluorometil)-4,5-dihidro-1H-pirazol-1-il)(2-hidroxifenil)metanona; N-(4-bromofenil)-2-(3-etil-5-hidroxi-5-(trifluorometil)-4,5-dihidro-1H-pirazol-1-il)-2-oxoacetamida; 2-(5-hidroxi-3-propil-5-(trifluorometil)-4,5-dihidro-1H-pirazol-1-il)-2-oxo-N-fenetilacetamida; N-(4-bromofenil)-2-(5-hidroxi-3-propil-5-(trifluorometil)-4,5-dihidro-1H-pirazol-1-il)-2-oxoacetamida;2-(3-butil-5-hidroxi-5-(trifluorometil)-4,5-dihidro-1H-pirazol-1-il)-2-oxo-N-fenetilacetamida; 40 2-(5-hidroxi-3-isobutil-5-(trifluorometil)-4,5-dihidro-1H-pirazol-1-il)-2-oxo-N-fenetilacetamida; N-(4-bromofenil)-2-(5-hidroxi-3-pentil-5-(trifluorometil)-4,5-dihidro-1H-pirazol-1-il)-2-oxoacetamida; 2-(5-hidroxi-3-pentil-5-(trifluoromemil)-4,5-dihidro-1H-pirazol-1-il)-N-(4-metoxifenil)-2-oxoacetamida; 2-(5-hidroxi-3-isopentil-5-(trifluorometil)-4,5-dihidro-1H-pirazol-1-il)-2-oxo-N-fenetilacetamida; 2-(5-hidroxi-3-isopentil-5-(trifluorometil)-4,5-dihidro-1H-pirazol-1-il)-N-(4-metoxifenil)-2-oxoacetamida; 2-(3-hexil-5-hidroxi-5-(trifluorometil)-4,5-dihidro-1H-pirazol-1-il)-N-(4-metoxifenil)-2-oxoacetamida; 2-(3-ciclohexil-5-hidroxi-5-(trifluorometil)-4,5-dihidro-1H-pirazol-1-il)-N-(2-metoxifenil)-2-oxoacetamida; (E)-2-hidroxi-N'-((2-hidroxinaftalen-1-il)metilen)benzohidrazida; (E)-2-hidroxi-N'-((1-hidroxinaftalen-2-il)metilen)benzohidrazida; (E)-N'-(3,5-dibromo-2-hidroxibenciliden)-2-hidroxibenzohidrazida; y (E)-N'-(5-bromo-2-hidroxibenciliden)-2-hidroxibenzohidrazida para su utilización en un procedimiento para mejorar la función cognitiva en un paciente que presenta una funcióncognitiva disminuida debido a neurotoxicidad por LDDA.

10. 发明专利

ES2401664T3 Procedimientos de modificación de oligómeros beta amiloides utilizando compuestos no peptídicos 未知
公开(公告)号：ES2401664T3
公开(公告)日：2013-04-23
申请号：ES07840403
申请日：2007-07-12
申请人： ACUMEN PHARMACEUTICALS INC
发明人： KRAFFT GRANT A , PRAY TODD , GOURE WILLIAM F
IPC分类号： A61K31/381 , A61P25/28
摘要： Compuesto seleccionado de entre el grupo constituido por N-(2-metoxi-fenil)-2-oxo-2-{N'-[3-oxo-3-tiofen-2-il-1-trifluorometil-prop-(Z)-ilideno]-hidrazino}-acetamida; éster etílico del ácido 2-{[1-(2-hidroxi-3-metoxi-fenil)-met-(E)-iliden-hidrazinooxalil]-amino}-6-metil-4,5,6,7- tetrahidro-benzo[b]tiofeno-3-carboxílico; éster etílico del ácido 2-{[1-(2-hidroxinaftalen-1-il)-met-(E)-iliden-hidrazinooxalil]-amino}-6-metil-4,5,6,7-tetrahidro- benzo[b]tiofeno-3-carboxílico; éster etílico del ácido 2-{[1-(2-hidroxifenil)-met-(E)-iliden-hidrazinooxalil]-amino}-6-metil-4,5,6,7-tetrahidro- benzo[b]tiofeno-3-carboxílico; 2-(5-hidroxi-3-isobutil-5-(trifluorometil)-4,5-dihidro-1H-pirazol-1-il)-N-(2-metoxifenil)-2-oxoacetamida; y (E)-2-hidroxi-N'-((1-hidroxinaftalen-2-il) metilen)benzohidrazida para su utilización en un procedimiento in vivo en un paciente que consiste en: (a) antagonizar la formación de LDDA neurotóxico del Aß1-42 monomérico poniendo en contacto Aß1-42 monomérico con dicho compuesto; o para (b) inhibir, regular y/o modular la disfunción neuronal y/o la neurotoxicidad provocadas por LDDA en una célula neuronal o tejido neuronal inhibiendo la formación de los LDDA que comprende poner en contacto los monómeros de Aß1-42 que pueden estar en presencia de células neuronales con una cantidad eficaz de dicho compuesto.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式